Sign in
Taking people in United StatesNo phase

Music therapy for quality of life in people with sickle cell disease

Tests music therapy against health education in teens and adults with sickle cell disease.

Key facts

Who runs it
University of California, Irvine
Where
Cleveland and Greenville, United StatesSee the 2 sites
Trial code
Registry title
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
Status
Recruiting
People taking part
90 people, planned
Started
2 Apr 2025
Expected to end
31 Jan 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Music therapy
  • Health education
Record updated
29 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for teenagers and adults with sickle cell disease who have had ongoing pain on most days for the past 6 months. It tests music therapy against health education.

Age
14 years or older
Sex
All sexes can join.
Disease stage
Sickle cell disease confirmed in the health record, with chronic pain on most days over the past 6 months. Pain must have limited daily activities on at least 1-2 days in the past week. A clinical exam must show a pain-related sign, and no other diagnosis should better explain the symptoms.
Earlier treatment
People cannot be currently doing mind-body therapies with a healthcare professional for pain. People who took part in the MUSIQOLS single-site pilot study in 2018 cannot join.
Biomarker or test result
Sickle cell disease confirmed by laboratory testing.

Main reasons for not taking part

  • Significant visual, hearing or cognitive impairment
  • Took part in the 2018 MUSIQOLS single-site pilot study at University Hospitals
  • Currently in mind-body therapy for pain with a healthcare professional
  • Major medical event planned in the next 14 weeks, such as childbirth, orthopedic surgery, gene therapy or stem cell transplant
  • Cannot speak and understand English, or has no email address and no mobile device with a data plan

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Be aged >=14 years old
  • Have a diagnosis of SCD present in their electronic health record (EHR)
  • Meet Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks-American Pain Society Pain Taxonomy (AAPT) criteria for chronic SCD pain which includes:; 3a. A diagnosis of SCD confirmed by laboratory testing (present in EHR per eligibility criteria 2); 3b. Reports of ongoing pain present on most days over the past 6 months either in a single location or in multiple locations (to be obtained at screening); 3c. Displaying at least one of the following signs on clinical exam (to be obtained from providers' clinical notes in the EHR
  • Palpation of the region of reported pain elicits focal pain or tenderness
  • Movement of the region of reported pain elicits focal pain
  • Decreased range of motion or weakness in the region of reported pain
  • Evidence of skin ulcer in the region of reported pain
  • Evidence of hepatobiliary or splenic imaging abnormalities (e.g., splenic infarct, chronic pancreatitis) consistent with the region of reported pain; or
  • Evidence of imaging abnormalities consistent with bone infarction or avascular necrosis in the region of reported; 3d. There is no other diagnosis that better explains the signs and symptoms (to be obtained from providers following referral and pre-screening); Be able to speak and understand English; Have an email address and access to mobile device with a functioning data plan; Reporting that pain interfered with daily activities at least 1-2 days in the past week

Who cannot take part

  • Have previously participated in the MUSIQOLS single-site pilot study at University Hospitals in 2018
  • Are currently engaging in mind-body therapies under the supervision of a healthcare professional specifically for pain management
  • Have a planned major medical event in the next 14 weeks such as (but not limited to) childbirth, orthopedic surgery, gene therapy, or stem cell transplant (These criteria do not include blood transfusions, exchange transfusions, or other pharmacologic pain treatment); Qualitative interviews will be conducted with ~24 participants who received the interventions (with equal numbers across the InMT, HybMT and HybHE groups). Participants will be purposively sampled to include equal distribution across sites in proportion to recruitment; Stakeholder surveys and qualitative interviews will be conducted among ~20 relevant staff stakeholders (~10 per site), including healthcare providers \& staff, music therapists and HybHE interventionists
  • Have a significant visual, hearing, or cognitive impairment

Where in United States

  • UH Seidman Cancer Center Adult SCD Clinic or UH Rainbow Babies and Children's Hospital Sickle Cell Anemia CenterCleveland, United StatesContact: Amma Owusu-Ansah, MD (principal investigator)Taking people
  • Prisma Health Lifespan Comprehensive SCD ProgramGreenville, United StatesContact: Alan Anderson, MD (principal investigator)Not yet recruiting

About the trial

What the trial wants to find out

This is a multi-site, multi-visit feasibility RCT of music therapy (MT) among adolescent and adult patients (aged 14 and older) with sickle cell disease (SCD).

Read full original descriptionShow less

Subjects will be randomized into one of three groups, either (1) 6 visits of in- person MT (InMT:); (2) 1 visit of in-person MT and 5 visits of virtual MT (HybMT); or (3) 1 visit of in-person health education and 5 visits of virtual health education (HybHE).

Cohorts of 15 participants (10 at site 1 and 5 site 2) will be recruited each quarter for 6 quarters to reach 90 participants. Cohorts will maintain a semi-structured recruitment, consenting, assessment, and intervention schedule.

The primary objective of the study is to examine the feasibility of study. This is defined by 6 metrics: (1) completeness of data collection, (2) participant screening, (3) participant recruitment, (4) participant retention, (5) Individual attendance and (6) Home practice. A final determination of "feasibility" for the study will be met if any 4 of the 6 metrics described above are met.

This study will also include a secondary objective of conducting qualitative interviews to assess feasibility of implementation.

The 3 groups in the trial

  • InMTTreatment being tested

    Participants in the InMT will receive 6 in-person MT sessions at the SCD center main campus, satellite campus, or another location preferred by the participant (e.g., community center).

    Treatment: Music therapy

  • HybMTTreatment being tested

    Individuals randomized to Hybrid MT will receive 1 in-person MT session at the SCD center main campus, satellite campus, or another location preferred by the participant (e.g., community center) and 5 virtual MT sessions over secure telehealth platform (e.g. Zoom Health Professional).

    Treatment: Music therapy

  • HybHEExisting treatment, for comparison

    Participants in the HybHE condition will receive 1 in-person health education session at the SCD center main campus, satellite campus, or another location preferred by the participant (e.g., community center) and 5 virtual sessions over secure telehealth platform (e.g. Zoom Health Professional).

    Treatment: Health education

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease (MULTI-MUSIQOLS)
Plain-language title
Music therapy for quality of life in people with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
29 January 2026